Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders. In one embodiment, the invention provides a pharmaceutical unit dosage form composition, comprising a compound of Formula (I)

##STR00001##

or a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof.

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders. In one embodiment, the invention provides a pharmaceutical unit dosage form composition, comprising a compound of Formula (I)

##STR00001##

or a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof.

Described herein are compositions and methods for treating Alzheimer's disease, a tauopathy disorder or dementia. The compositions include mammalian suppressor of taupathy 2 (MSUT2) inhibitors. The methods include steps for identifying candidate compositions capable of inhibiting RNA binding proteins to poly(A) RNA and detecting RNA polyadenylation of poly(A) RNA. The methods include reducing accumulation of phosphorylated and aggregated human tau.

Described herein are compositions and methods for treating Alzheimer's disease, a tauopathy disorder or dementia. The compositions include mammalian suppressor of taupathy 2 (MSUT2) inhibitors. The methods include steps for identifying candidate compositions capable of inhibiting RNA binding proteins to poly(A) RNA and detecting RNA polyadenylation of poly(A) RNA. The methods include reducing accumulation of phosphorylated and aggregated human tau.

The disclosure provides compounds that inhibit the invasion of host cells by intracellular parasites. These find use, for example, in treating and preventing periodontitis or a periodontitis-related condition or symptom.

The disclosure provides compounds that inhibit the invasion of host cells by intracellular parasites. These find use, for example, in treating and preventing periodontitis or a periodontitis-related condition or symptom.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THRβ agonist.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THRβ agonist.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and an SSAO inhibitor.